Abstract
As new COVID-19 variants emerge, it’s vital to understand how certain populations are affected. Sparse data exists on whether vaccinated patients with prior cutaneous malignancies are at higher risk for adverse events or breakthrough infections (BI) compared to the general population. Therefore, we examined the safety and efficacy of the COVID-19 vaccine in skin cancer patients. A retrospective study using TriNetX, a multicenter database of ∼80 million records, was completed. Patients who completed a mRNA COVID-19 vaccine sequence or received an additional booster were identified up to November 15th 2021 and divided into two cohorts based on history of skin cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
